Scientists hunt for biomarkers to personalize head and neck cancer treatment

NCT ID NCT07211139

Recruiting now Knowledge-focused Sponsor: Samsung Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is analyzing blood and tumor samples from 30 people with advanced head and neck cancer who are receiving standard immunotherapy plus chemotherapy. The goal is to find biological markers that can predict who will respond well to treatment. By understanding changes in the tumor and immune system, researchers hope to develop more personalized treatment strategies in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: immune checkpoint inhibitors and cytotoxic chemotherapy
What this could lead to: If successful, this could help doctors identify which head and neck cancer patients are most likely to benefit from immunotherapy, leading to more personalized and effective treatment plans.
What could go wrong: This is a small, early-stage exploratory study with only 30 participants, so results may not apply to all patients. It focuses on understanding biomarkers rather than testing a new treatment, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.